Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
Roche,Bevacizumab,"Ovarian cancer, advanced, 1st line",Bevacizumab (Avastin),Community and Hospital,Oncology Agents and Immunosuppressants
